JP2022515487A5 - - Google Patents
Info
- Publication number
- JP2022515487A5 JP2022515487A5 JP2021537771A JP2021537771A JP2022515487A5 JP 2022515487 A5 JP2022515487 A5 JP 2022515487A5 JP 2021537771 A JP2021537771 A JP 2021537771A JP 2021537771 A JP2021537771 A JP 2021537771A JP 2022515487 A5 JP2022515487 A5 JP 2022515487A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequences
- sequence numbers
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103100A JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/125052 | 2018-12-28 | ||
| CN2018125052 | 2018-12-28 | ||
| CN2019095827 | 2019-07-12 | ||
| CNPCT/CN2019/095827 | 2019-07-12 | ||
| PCT/CN2019/129017 WO2020135674A1 (en) | 2018-12-28 | 2019-12-27 | Claudin18.2 binding moieties and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103100A Division JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515487A JP2022515487A (ja) | 2022-02-18 |
| JP2022515487A5 true JP2022515487A5 (https=) | 2022-11-24 |
Family
ID=71127698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537771A Pending JP2022515487A (ja) | 2018-12-28 | 2019-12-27 | クローディン１８．２結合部分およびその利用 |
| JP2024103100A Active JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103100A Active JP7724332B2 (ja) | 2018-12-28 | 2024-06-26 | クローディン１８．２結合部分およびその利用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12258418B2 (https=) |
| EP (1) | EP3902839A4 (https=) |
| JP (2) | JP2022515487A (https=) |
| KR (1) | KR20210110339A (https=) |
| CN (1) | CN113227146B (https=) |
| AU (1) | AU2019415848A1 (https=) |
| BR (1) | BR112021012608A2 (https=) |
| CA (1) | CA3125193A1 (https=) |
| IL (1) | IL284393A (https=) |
| MX (1) | MX2021007939A (https=) |
| SG (1) | SG11202106534RA (https=) |
| WO (1) | WO2020135674A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3971208A4 (en) * | 2019-05-16 | 2022-11-30 | Qilu Pharmaceutical Co., Ltd. | ANTIBODIES TO CLAUDIN 18A2 AND USE THEREOF |
| AU2020378502A1 (en) | 2019-11-05 | 2022-06-16 | LaNova Medicines Limited | Antibody-drug conjugates targeting claudin 18.2 |
| JP7392145B2 (ja) | 2019-12-20 | 2023-12-05 | 山東博安生物技術股▲ふん▼有限公司 | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム |
| CN113637082A (zh) * | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 |
| WO2022002112A1 (en) | 2020-07-01 | 2022-01-06 | Shandong Boan Biotechnology Co., Ltd. | Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody |
| CN111808194B (zh) * | 2020-07-13 | 2021-04-20 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| CA3196930A1 (en) * | 2020-09-28 | 2022-03-31 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-claudin18 antibodies |
| WO2022098972A1 (en) | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
| CN114539402B (zh) * | 2020-11-27 | 2025-06-13 | 南京北恒生物科技有限公司 | 靶向Claudin18.2的抗体及其用途 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| TW202241519A (zh) | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| CN113321730B (zh) * | 2021-01-11 | 2023-10-10 | 上海莱馥医疗科技有限公司 | Cldn18.2抗体及其应用 |
| WO2022166940A1 (en) * | 2021-02-08 | 2022-08-11 | Shandong Boan Biotechnology Co., Ltd. | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| WO2022206975A1 (zh) * | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
| AU2022275043B2 (en) | 2021-05-08 | 2025-11-20 | Remegen Co., Ltd. | Anti-Claudin 18.2 antibody and antibody-drug conjugate thereof |
| KR20230132640A (ko) | 2022-03-04 | 2023-09-15 | 앱티스 주식회사 | 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법 |
| KR20240125071A (ko) | 2022-11-01 | 2024-08-19 | 앱티스 주식회사 | Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN116284224B (zh) * | 2023-05-12 | 2023-07-25 | 中国农业大学 | 一种结合Claudin 18.2的环肽及其应用 |
| WO2025038602A1 (en) * | 2023-08-14 | 2025-02-20 | Ginkgo Bioworks, Inc. | Immune cell stimulatory sequences |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072299A1 (en) * | 2023-09-25 | 2025-04-03 | Duke University | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
| WO2025251228A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Cldn18.2-targeting chimeric antigen receptor and engineered cell |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN120518772A (zh) * | 2014-07-17 | 2025-08-22 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| US11059887B2 (en) * | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| JP7767270B2 (ja) * | 2019-08-20 | 2025-11-11 | スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド | 新規抗ｃｌｄｎ１８．２抗体 |
-
2019
- 2019-12-27 KR KR1020217023724A patent/KR20210110339A/ko active Pending
- 2019-12-27 BR BR112021012608-2A patent/BR112021012608A2/pt unknown
- 2019-12-27 EP EP19906510.3A patent/EP3902839A4/en active Pending
- 2019-12-27 AU AU2019415848A patent/AU2019415848A1/en active Pending
- 2019-12-27 SG SG11202106534RA patent/SG11202106534RA/en unknown
- 2019-12-27 CA CA3125193A patent/CA3125193A1/en active Pending
- 2019-12-27 WO PCT/CN2019/129017 patent/WO2020135674A1/en not_active Ceased
- 2019-12-27 MX MX2021007939A patent/MX2021007939A/es unknown
- 2019-12-27 CN CN201980085449.3A patent/CN113227146B/zh active Active
- 2019-12-27 JP JP2021537771A patent/JP2022515487A/ja active Pending
- 2019-12-27 US US17/419,203 patent/US12258418B2/en active Active
-
2021
- 2021-06-27 IL IL284393A patent/IL284393A/en unknown
-
2024
- 2024-06-26 JP JP2024103100A patent/JP7724332B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515487A5 (https=) | ||
| JP2021534762A5 (https=) | ||
| JP2021522801A5 (https=) | ||
| JP2020062036A5 (https=) | ||
| JP2022512132A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| JP2017514461A5 (https=) | ||
| JP2023543031A5 (https=) | ||
| JP2014158469A5 (https=) | ||
| JP2018035138A5 (https=) | ||
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2019533719A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| JP2010509931A5 (https=) | ||
| JP2025092589A5 (https=) | ||
| WO2008004834A1 (en) | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor | |
| JP2023516004A5 (https=) | ||
| JP2020522488A5 (https=) | ||
| US20250136720A1 (en) | Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer | |
| JP2023540526A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JP2020502233A5 (https=) |